BioSpace News Archive

Leidos (NYSE: LDOS), a FORTUNE® 500 science and technology leader, was recently awarded a new project agreement by the Defense Threat Reduction Agency (DTRA) to conduct clinical studies of therapeutics for treating COVID-19.

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced the presentation of a new analysis from the MAGNIFY-MS study on MAVENCLAD® (cladribine) tablets in patients with relapsing multiple sclerosis (RMS) at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2021

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands, today announced that members of its management team will participate in two upcoming investor conferences:

Over 99.8% success rate on deliveries resulted in over 9,500 additional patients treated and potential of additional 690 live births via CryoStork® reproductive medicine solution

Agendia, Inc., a world leader in precision oncology for breast cancer, today announced its participation in the Cowen 41st Annual Healthcare Conference, which takes place March 1-4, 2021.

MedX Health Corp. is pleased to announce that it has closed on the final $1.4 million of the $4 million Non-brokered Private Placement of 80 Convertible Debenture Loan Notes, each with a face value of $50,000, as originally announced in its Press Release dated January 25, 2021.

ChemoCentryx, Inc., announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences:.

Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today the publication of the results of its previously completed Phase 2a study of EB612 in the Journal of Bone and Mineral Research.

Invisalign brand sponsorship to reach Warriors fans globally through different fan experiences – arena, digital, and esports

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today the pricing of its underwritten public offering of 15,000,000 common shares and warrants